Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Composite Danshen Pill for vascular lesions in type 2 diabetes
ChiCTR-IPR-15006501Phase 4Not yet recruiting
- Sponsor
- Shuguang Hospital
- Start
- Oct 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of compound salvia miltiorrhiza in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shuguang Hospital. Primary endpoints: Urine albumin, Urine creatinine and 1 more. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
compound salvia miltiorrhiza
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-15006501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006501.